Core Thesis - Bristol-Myers Squibb Company (BMY) is considered modestly undervalued, trading at about a 20% discount to its fair value, with potential for an estimated annual alpha of roughly 7% if the price adjusts to intrinsic value within three years [2]. Financial Performance - BMY's revenue remained steady at around $19–22 billion from 2015 to 2018, reflecting streamlined operations after divestitures [2]. - The pivotal shift in revenue occurred in 2020 with the acquisition of Celgene, increasing revenue from approximately $26 billion to $42.5 billion, driven by high-margin oncology drugs [3]. - Sales growth has normalized post-acquisition, with projected sales hovering near $46–48 billion from 2021 to 2024, as strong performance from Eliquis and Opdivo offsets declines in Revlimid due to generic competition [3]. - The company's compound annual growth rate over the past decade is about 12%, while organic growth excluding Celgene is in the low- to mid-single digits [3]. Valuation Insights - The valuation model assumes a weighted average cost of capital (WACC) of 6.7% and a 10.8x EBITDA exit multiple, estimating the enterprise value at approximately $155 billion [4]. - This implies an intrinsic share value between $47 and $59, compared to the current trading level of around $46 [4]. Investment Sentiment - Despite the modest undervaluation, there is a preference to wait for a deeper discount before entering, due to limited growth visibility and execution risk [4]. - BMY is not among the 30 most popular stocks among hedge funds, with 67 hedge fund portfolios holding BMY at the end of the second quarter, down from 69 in the previous quarter [6].

Core Insights - The article introduces a new contributing analyst, Ryne Mauck, who focuses on investment ideas and encourages submissions from other investors [1] - The analyst emphasizes a fundamental equity research approach, aiming to identify companies trading at significant discounts to their intrinsic value [2] - The investment philosophy is centered on rational decision-making, downside protection, and independent thinking, with a focus on long-term value investing [2] Company and Industry Analysis - The analyst has a beneficial long position in KOF shares, indicating a positive outlook on the company's performance [3] - The article does not provide specific financial metrics or performance data related to KOF or other companies [4]

Core Insights - Berkshire Hathaway's cash reserves reached a record $381.7 billion in the last quarter, with operating profit increasing by 34% due to strong insurance performance and low disaster activity [1] - The company is currently not engaging in mergers and acquisitions, raising questions about Warren Buffett's investment strategy as he prepares to hand over CEO responsibilities to Greg Abel at the end of the year [1][2] Financial Performance - The cash pile is comparable to major companies like Procter & Gamble and Home Depot, indicating significant liquidity [2] - Despite the large cash reserves, Buffett has been a net seller of equities, offloading $6 billion, which suggests a cautious approach to current market valuations [2][3] - The net investment income has decreased quarter over quarter due to falling short-term interest rates, impacting overall returns [3][4] Market Position and Strategy - The lack of share buybacks by Berkshire Hathaway implies that the company does not view its shares as undervalued, which could indicate a broader market perception of fair or high valuations [5][6] - Buffett's recent investments include a stake in UnitedHealth for $1.6 billion, but overall, he has expressed a lack of opportunities in the current market [6][7] - The ongoing M&A activity in the market, valued at approximately $4 trillion, contrasts with Berkshire's current strategy of remaining on the sidelines [5][7]

Cryptocurrency Analysis - Trump coin lacks intrinsic value and faces dilution due to periodic unlocks, making it a potential short opportunity [1] - Bitcoin possesses intrinsic value, supported by investors valuing it at $120,000 [2] Market Sentiment - Bitcoin's price appreciation is attributed to increasing awareness and adoption, with new investors recognizing its value [3][4] - The market views Bitcoin differently from fiat currencies, suggesting a shift in perception towards its underlying value [3]

Core Thesis - Crocs, Inc. is viewed positively due to its asset-light model, high margins, and significant cash generation potential, with shares trading below intrinsic value estimates of $140–$175 per share [4][5]. Financial Performance - As of September 23rd, Crocs' share price was $78.15, with trailing and forward P/E ratios of 21.24 and 8.58, respectively [1]. - The company generated $992.5 million in operating cash flow and approximately $923 million in free cash flow in 2024, achieving a return on invested capital (ROIC) of around 27% [3]. - Crocs maintains a manageable balance sheet with net debt of approximately $1.2 billion, actively reducing this through buybacks and selective debt paydowns [3]. Business Model and Strategy - Crocs operates as a global footwear brand with a focus on high-margin products, primarily through its core clogs and the HEYDUDE brand, with direct-to-consumer (DTC) sales accounting for roughly 50% of 2024 revenue [2]. - The company benefits from superior gross margins of 58.8% and operating margins of 24.9%, driven by improved pricing control and low SKU complexity [2]. - Growth strategies include simple product architecture, viral collaborations, and international expansion, with HEYDUDE integration aimed at replicating Crocs' disciplined margin and inventory management [3]. Market Position and Valuation - The stock is currently trading at approximately $77, which is below its estimated intrinsic value, presenting an asymmetric risk/reward profile [4]. - The company emphasizes long-term operating margins around 24% and prioritizes capital allocation towards share repurchases and deleveraging over dividends [3]. Risks and Challenges - Near-term risks include fashion volatility, tariff exposure, and the necessity to maintain channel discipline as the DTC mix increases [4].

Core Viewpoint - Concerns have been raised regarding Tesla's growth potential and valuation sustainability, leading to a significant exit from the company's stock by The Future Fund [1][2]. Valuation Concerns - Tesla currently trades at a forward price-to-earnings (P/E) ratio of 180x based on projected 2025 earnings, which is deemed unprecedented for a $1 trillion company [4]. - Future P/E ratios for 2026 and 2029 are estimated at 120x and 45x, respectively, indicating a perceived valuation imbalance [4]. - The projected slowdown in earnings has led Wall Street to reduce Tesla's earnings estimates for 2026 and 2028 by 25% to 40% [5]. Growth Prospects - The integration of emerging technologies like Robotaxis and the Optimus humanoid robot may contribute to a slowdown in Tesla's growth rate [2][3]. - Analysts predict that as forecasts extend to 2029 and beyond, Tesla's forward growth rate will decline [3]. Investment Strategy - The Future Fund's exit from Tesla stock is based on long-term fundamentals rather than short-term market sentiment, emphasizing a disciplined investment strategy focused on intrinsic value [2][6]. - True valuation should consider the present value of all future cash flows, rather than just short-term results [6]. Market Performance - Tesla's stock has recently lost momentum, closing down over 3% at $346.46, with a year-to-date decline of nearly 9% [7]. - Broader challenges include declining sales and backlash related to CEO Elon Musk's political views, although Musk's recent exit from a government advisory role may be seen as a potential catalyst for renewed growth [9].